Please login to the form below

Not currently logged in

Breakthrough status for GSK/ Genmab's Arzerra

Speeds up FDA review for use in chronic lymphocytic leukaemia

FDA headquarters White Oak 

A new drug in development at GlaxoSmithKline (GSK) and Genmab for the most common form of adult leukaemia has been granted breakthrough status by the US Food and Drug Administration (FDA).

Arzerra (ofatumumab) has been submitted for approval in the US as a treatment alongside chlorambucil for patients with chronic lymphocytic leukaemia (CLL) who have not received prior treatment and are inappropriate for fludarabine-based therapy.

For Danish company Genmab it is a major achievement, as both of its lead drug programmes have now been designated breakthroughs by the US regulator.  The company's multiple myeloma therapy daratumumab - which is partnered with Johnson & Johnson - was awarded this status in May.

In trials, first-line treatment with Arzerra plus chlorambucil improved progression-free survival (PFS) in CLL patients and approval in this setting is considered to be critical for the drug's commercial success.

GSK has been selling Arzerra as a second-line therapy in CLL patients who are refractory to treatment with fludarabine and alemtuzumab since 2009, but sales have been modest - just £60m ($96m) last year for example - as the company has struggled to differentiate its product from Roche's Rituxan/ MabThera (rituximab) in the marketplace.

Breakthrough status is intended to accelerate development and review of drugs to treat serious medical conditions when preliminary clinical evidence shows "substantial improvement on at least one clinically significant endpoint over available therapies", notes GSK.

Breakthrough designation means that the company will have a higher level of contact with the FDA during the review process, which should also be shorter.

A few weeks ago Arzerra was one of a handful of already-marketed drugs that GSK chief executive Sir Andrew Witty said would be 'slow-burners', gradually building up sales momentum with the addition of new indications.

The anti-CD20 antibody is a direct competitor to Rituxan, sharing the same molecular target, but unlike its rival has been unable to show robust efficacy in indications such as non-Hodgkin's lymphoma, a much larger market than CLL.

It remains in phase III testing for other indications however, including relapsed CLL, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and is also in phase II as a therapy for multiple sclerosis.

16th September 2013

From: Sales, Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....